Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension studyPaul Harmatz, Stuart J. Swiedler, Roberto Giugliani et al.|The Journal of Pediatrics|2006Cited by 364
Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and managementElizabeth Braunlin, Roberto Giugliani, James P. Loehr et al.|Journal of Inherited Metabolic Disease|2011Cited by 302
Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatasePaul Harmatz, Celeste Decker, Roberto Giugliani et al.|Molecular Genetics and Metabolism|2008Cited by 216
Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo‐controlled studyChristian J. Hendriksz, Wolfgang Dummer, Barbara K. Burton et al.|Journal of Inherited Metabolic Disease|2014Cited by 211
Multidisciplinary Management of Hunter SyndromeJoseph Muenzer, Ed Wraith, Michael Beck et al.|PEDIATRICS|2009Cited by 193